Register for our free email digests:
Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Alvogen Strikes Deals For Pfenex’ Teriparatide
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Aurobindo Co-Founder Hit With $3m Fine For Insider Trading
Indian stock market regulator SEBI has slapped the billionaire founder of Aurobindo Pharma, along with other promoters of the company, with a more than $3m fine for allegedly violating insider trading norms over a string of licensing agreements with multinational Pfizer.
Lannett Strikes Deal For Respirent’s US Advair Rival
Lannett has struck a deal giving it exclusive US distribution rights for 10 years to a generic version of Advair Diskus being developed by China’s Respirent.
Biocon Acquires Pfizer R&D Center In India
Biocon Biologics has acquired a biologics research facility in southern India from Pfizer that will employ 250 scientists and enable the company to pursue “breakthrough innovation.”
Nichi-Iko And Eisai Expand Alliance To China
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Juno And Celltrion Partner For Australian Biosimilars Push
Australia’s Juno Pharmaceuticals has struck a deal with Korea’s Celltrion to partner on marketing biosimilar trastuzumab and rituximab.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.